Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of Moderate Buy from Analysts

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have received a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 […]

Related Keywords

United States ,America ,William Blair ,Mark Coleman ,Axsome Therapeutics Inc ,Fifth Third Bancorp ,Tower Research Capital ,Harbour Investments Inc ,Axsome Therapeutics Company Profile ,Nasdaq ,Third Bancorp ,Axsome Therapeutics ,Get Free Report ,Director Mark Coleman ,Financial Advisors ,Research Capital ,Dark Forest Capital Management ,Get Free ,Axsome Therapeutics Daily ,Nasdaq Axsm ,Axsm ,Medical ,Ratings ,Consensus ,